Talus Bio
Facts
Is this your organization? Claim it
Talus Bio names Chris Joyce, MBA as VP of Business Development to drive pharma deals and advance TF therapeutics
Talus Bio hired Chris Joyce, MBA as VP of Business Development to accelerate pharma partnerships and advance its transcription factor therapeutics, including two programs targeting TBXT for non-small cell lung cancer and NONO-related androgen receptor splicing in castration-resistant prostate cancer.
Talus Bio launches 'Drugging the Undruggable' blog series to advocate open-source science and structure-free drug discovery
Talus Bio launched a new blog series, Drugging the Undruggable, to promote open-source computational science and explain their structure-free AI approach to targeting intrinsically disordered proteins.
Talus Bio names Gaelle Mercenne, PhD as Head of Biology to advance AI-driven transcription factor drugs
Talus Bio hires Dr. Gaelle Mercenne as Head of Biology to lead preclinical development and AI-driven lead optimization for its transcription factor therapeutics, using the MARMOT platform and funds from an $11.2M seed extension to expand its discovery team.
Talus Bioscience Raises $11.2M Seed+ Round Led by Two Bear Capital to Expand MARMOT AI Platform for Transcription Factor Therapeutics
Talus Bioscience raised $11.2M in Seed+ funding led by Two Bear Capital to expand its MARMOT AI platform that discovers and optimizes transcription factor modulators, accelerating programs targeting Brachyury-driven cancers and a prostate cancer–linked transcription factor.
Talus Bio Raises $9.75M Seed Round to Advance MARMOT Platform and Appoints Michelle Briscoe as COO
Talus Bio, a Seattle biotech founded in 2020, raised $9.75 million in seed funding to advance its MARMOT platform for discovering drugs that target hard-to-drug transcription factors and hired Michelle Briscoe as COO.
Senior Data Scientist Joins Talus Bioscience After Postdoc and Challenging 2020 Faculty Job Market
A senior data scientist explains why they left academia to join Seattle biotech Talus Bioscience, describing their postdoc experience, the faculty job market struggles in 2020, and factors that led them to accept a startup role.
